Abbott Laboratories reported strong financial results for the June quarter, trading at USD 102.35 on September 19, 2026. The company posted earnings per share of USD 1.31, which beat analyst estimates by USD 0.03. Revenue reached USD 12.59 billion, representing a significant year-over-year increase of 13.0 percent. Looking ahead, Abbott provided guidance for the third quarter of 2026 with EPS expected between USD 1.38 and USD 1.46. The full-year fiscal 2026 outlook was set at USD 5.45 to USD 5.60 per share. This forward-looking guidance positions the company's annual earnings expectations above the current analyst consensus of USD 5.52. Wall Street analysts have responded positively to the results, with BTIG Research raising its price target to USD 134 and Wolfe Research lifting Abbott to an outperform rating with a USD 130 target. Despite these upgrades, the current share price remains below the consensus target of USD 119.50, suggesting potential upside for investors. Abbott Laboratories operates within the Health Care Equipment & Supplies sector with a market capitalization of USD 177.11 billion. The stock has a 52-week trading range between USD 81.97 and USD 137.49, indicating volatility but maintaining a position well above its yearly low following the recent earnings beat.